

Michael Crider

Chair and Associate Dean for Research, College of Pharmacy, Pharmaceutical Sciences, SIUE

Somatostatin subtype 4 Agonists as potential agents for Alzheimer's disease and dopamine D3 agonists for the potential treatment of Parkinson's disease.



Phone: 618-650-5162
mcrider@siue.edu

Somatostatin subtype 4 agonists- project: We have shown that NNC-26-9100 and related analogs can enhance memory and learning in mice. Furthermore, these analogs have the potential to degrade beta-amyloid, a key contributor in Alzheimer's disease.

The second project deals with the development of dopamine D3 analogs as potential agents for the treatment of Parkinson's disease and related central nervous system disorders. The lead compound 8-OH-PBZI was made in my laboratory in the early 1990's. The chemistry and preliminary pharmacology was published. The compound is sold as a research chemical by several companies. We did not pursue patent coverage on this compound.



2014 SIU INNOVATION EXPO
WWW.TIE.SIU.EDU